Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis
- PMID: 20045200
- DOI: 10.1016/j.tins.2009.12.002
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis
Abstract
Multiple sclerosis (MS), an incurable but manageable disorder, is characterized by chronic inflammatory demyelination and neurodegeneration in the central nervous system. Although the primary cause of this often devastating disease remains elusive, major therapeutic advances have occurred during the past two decades. Here, we present a review of current immunomodulatory treatments and outline upcoming therapy approaches, including biologics and oral alternatives that might have equivalent or superior efficacy and/or enhanced tolerability compared with available treatments, and discuss the scientific rationale and expected benefits and risks for these compounds. We also speculate about alternatives beyond immune-directed approaches, review novel insights into the neurobiological consequences of sustained brain inflammation and evaluate future perspectives for neuroprotective and neuroregenerative treatment strategies for MS.
Copyright 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
The future of multiple sclerosis treatment.J Neurol Sci. 2009 Feb 1;277 Suppl 1:S55-61. doi: 10.1016/S0022-510X(09)70015-2. J Neurol Sci. 2009. PMID: 19200869
-
Linkage between immunomodulation, neuroprotection and neurogenesis.Drug News Perspect. 2009 Jul-Aug;22(6):301-12. doi: 10.1358/dnp.2009.22.6.1395253. Drug News Perspect. 2009. PMID: 19771319 Review.
-
Novel therapeutic options for multiple sclerosis.Expert Rev Clin Pharmacol. 2014 Jan;7(1):91-104. doi: 10.1586/17512433.2014.865517. Epub 2013 Dec 10. Expert Rev Clin Pharmacol. 2014. PMID: 24325127 Review.
-
Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.Exp Neurol. 2007 Jan;203(1):1-4. doi: 10.1016/j.expneurol.2006.09.007. Epub 2006 Oct 25. Exp Neurol. 2007. PMID: 17069803 Review. No abstract available.
-
Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis.J Neurol Sci. 2009 Dec 15;287(1-2):17-26. doi: 10.1016/j.jns.2009.08.057. Epub 2009 Sep 16. J Neurol Sci. 2009. PMID: 19758606 Review.
Cited by
-
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist.Sci Signal. 2013 Oct 22;6(298):ra93. doi: 10.1126/scisignal.2004350. Sci Signal. 2013. PMID: 24150254 Free PMC article.
-
[Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Nervenarzt. 2015 Aug;86(8):960-70. doi: 10.1007/s00115-015-4369-7. Nervenarzt. 2015. PMID: 26187544 German.
-
The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.Mol Med. 2011 May-Jun;17(5-6):442-7. doi: 10.2119/molmed.2011.00077. Epub 2011 Feb 25. Mol Med. 2011. PMID: 21373721 Free PMC article. Review.
-
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.Biologics. 2016 Sep 12;10:119-38. doi: 10.2147/BTT.S89218. eCollection 2016. Biologics. 2016. PMID: 27672308 Free PMC article. Review.
-
Lipid biochemical changes detected in normal appearing white matter of chronic multiple sclerosis by spectral coherent Raman imaging.Chem Sci. 2018 Jan 2;9(6):1586-1595. doi: 10.1039/c7sc03992a. eCollection 2018 Feb 14. Chem Sci. 2018. PMID: 29675203 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous